XENON PHARMACEUTICALS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.83 USD | -0.86% |
|
-3.10% | -17.87% |
Financials (USD)
| Sales 2024 * | 1.88M | Sales 2025 * | 9.39M | Capitalization | 2.88B |
|---|---|---|---|---|---|
| Net income 2024 * | -225M | Net income 2025 * | -269M | EV / Sales 2024 * | 1,148 x |
| Net cash position 2024 * | 727M | Net cash position 2025 * | 650M | EV / Sales 2025 * | 237 x |
| P/E ratio 2024 * |
-13.1
x | P/E ratio 2025 * |
-11.9
x | Employees | 255 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.44% |
More Fundamentals
* Assessed data
More news
Latest transcript on Xenon Pharmaceuticals Inc.
More recommendations
More press releases
| 1 day | -1.18% | ||
| 1 week | -3.74% | ||
| Current month | -1.29% | ||
| 1 month | -12.99% | ||
| 3 months | -18.23% | ||
| 6 months | -2.72% | ||
| Current year | -18.41% |
1 week
37.34
39.94
1 month
37.1643.63
Current year
37.1650.99
1 year
27.9950.99
3 years
14.6550.99
5 years
7.0050.99
10 years
2.1050.99
| Managers | Title | Age | Since |
|---|---|---|---|
Ian Mortimer
CEO | Chief Executive Officer | 48 | 13-10-20 |
Sherry Aulin
DFI | Director of Finance/CFO | 41 | 10-12-31 |
| Chief Tech/Sci/R&D Officer | 53 | 21-08-22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Clarence Machado
BRD | Director/Board Member | 60 | 20-11-04 |
Justin Gover
BRD | Director/Board Member | 53 | 23-08-07 |
Gary Patou
BRD | Director/Board Member | 65 | 03-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.96% | 14 M€ | -3.05% | ||
| 0.22% | 0 M€ | 0.00% | - | |
| 0.22% | 0 M€ | 0.00% | - | |
| 0.20% | 12 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 37.83 | -0.86% | 404 768 |
| 24-06-05 | 38.16 | +0.16% | 301,826 |
| 24-06-04 | 38.1 | -0.88% | 683,087 |
| 24-06-03 | 38.44 | +0.97% | 354,602 |
| 24-05-31 | 38.07 | -2.48% | 778,149 |
Delayed Quote Nasdaq, June 06, 2024 at 12:05 pm EDT
More quotes
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Companyâs product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
38.16
USD
Average target price
58.79
USD
Spread / Average Target
+54.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.41% | 2.88B | |
| +18.33% | 125B | |
| +14.34% | 109B | |
| -2.58% | 24.74B | |
| +2.71% | 22.67B | |
| -9.95% | 18.14B | |
| -41.48% | 16.67B | |
| -12.48% | 16.64B | |
| +0.04% | 13.45B | |
| +23.28% | 11.32B |
- Stock Market
- Equities
- XENE Stock
